Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Crenolanib in Recurrent/Refractory Glioblastoma with PDGFRA Amplification
NCT02626364Phase 2Completed
- Sponsor
- AROG Pharmaceuticals, Inc.
- Start
- Apr 2016
- Primary completion
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of crenolanib in glioblastoma (GBM), sponsored by AROG Pharmaceuticals, Inc. Primary endpoint: Progression-free survival at 6 months. Started Apr 2016; status: completed.
02
Drugs
crenolanib
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT02626364.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02626364.